8215 results about "Immunology" patented technology

The present disclosure relates generally to methods for treating cancer with a KRAS inhibitor in combination with an immune checkpoint inhibitor, and more specifically to treating cancer with a pyridopyrimidine derivative in combination with a PD-1 or PD-L1 inhibitor.

Described herein are methods and systems for a conversational assistant that may be configured for use with one or more applications. The disclosed systems and methods may be configured as an outer loop / inner loop architecture incorporating one or more large language models (LLMs) and / or RAG functionality to support dialog-based interactions.

The present disclose includes, among other things, methods of treating or lessening the severity of CFTR-mediated disease or disorders.

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

The present disclose includes, among other things, methods of treating or lessening the severity of CFTR-mediated disease or disorders.

The invention relates to application of a targeted inhibition circPDK1 reagent in preparation of an anti-esophageal cancer drug, and belongs to the field of biological medicines. The reagent for targeted inhibition of circPDK1 expression provided by the invention is shRNA or siRNA, and in-vivo and in-vitro experiments prove that the reagent can significantly inhibit circPDK1 expression and inhibit growth and migration of esophageal cancer tumor cells; after siRNA of targeted annular circPDK1 is packaged into efficient and low-toxicity LNP-siRNA, circPDK1 expression is specifically silenced, proliferation and migration of esophageal cancer tumors can be remarkably inhibited, and a basis is provided for clinical treatment and scientific research of esophageal cancer related circRNA.

The invention discloses an N-sugar chain marker combination for predicting the curative effect state of IgA and IgG type MM and a prediction scoring system and application of the N-sugar chain marker combination. The N-sugar chain marker combination is composed of the following 11 N-sugar chains: NGA2, NGA2F, NG1A2F-1, NG1A2F-2, NA2, NA2F, NA2FB, NA3, NA3Fb, NA4 and NA4Fb. The method has the advantages that (1) the relevance between the N-carbohydrate chain and the curative effect in the blood of the IgA and IgG type MM patients in different curative effect states is found for the first time, and the N-carbohydrate chain can be used as an index for predicting the curative effect states of the IgA and IgG type MM patients for the first time; and (2) the N-carbohydrate chain curative effect prediction scoring system provided by the invention is used for predicting the curative effect states of IgA and IgG type MM patients, and a new technical means is provided for predicting the curative effects of the IgA and IgG type MM patients.

The invention discloses application of an MCU (microprogrammed control unit) inhibitor in preparation of a medicine for preventing or treating intestinal ischemia-reperfusion injury, and relates to the technical field of biological medicine, and the MCU inhibitor comprises one or two of a reagent for inhibiting MCU gene expression and a reagent for inhibiting MCU protein activity. The MCU inhibitor disclosed by the invention is beneficial to relieving intestinal mucosa injury and inflammatory change of intestinal tissues, improving completeness of a villus structure, reducing pathological injury degree score of the intestinal tissues and relieving cell apoptosis degree in the intestinal tissues, so that the MCU inhibitor is beneficial to relieving programmed death of intestinal mucosa cells; as a main component, the pharmaceutical composition is beneficial for preventing or treating intestinal ischemia-reperfusion injury.

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.

The disclosure provides methods for the diagnosis of Huntington's disease. In some embodiments, the method comprises detecting one or more repeat associated non-ATG (RAN) proteins in a biological sample.

The invention discloses a PD-1 (programmed death-1) monoclonal antibody and application thereof, the invention provides the monoclonal antibody, an antibody heavy chain complementarity determining region comprises CDR-H1, CDR-H2 and CDR-H3 which are respectively shown as SEQ ID NO.1-3, and an antibody light chain complementarity determining region comprises CDR-L1, CDR-L2 and CDR-L3 which are respectively shown as SEQ ID NO.4, LAS (LAS) and SEQ ID NO.5.

The invention relates to a monoclonal antibody with anticoagulant activity and application thereof, the antibody or fragment comprises a light chain variable region and a heavy chain variable region, and the amino acid sequence of the light chain variable region of the antibody or fragment is as shown in SEQ ID NO: 1; the amino acid sequence of the variable region of the heavy chain is as shown in SEQ ID NO: 3. The monoclonal antibody disclosed by the invention has the effect of inhibiting the activity of a co-coagulation pathway in a coagulation cascade reaction, and can be applied to prevention and treatment of thrombotic diseases.

The invention provides an antibody specifically combined with CDH6 (cadherin 6) and application thereof, and particularly discloses mouse and humanized antibodies combined with CDH6 as well as a preparation method and application thereof, and the mouse and humanized antibodies have better affinity with CDH6 protein and better endocytosis activity, so that the mouse and humanized antibodies can be applied to preparation of medicines for treating tumors and the like.

The present disclosure provides bispecific chimeric antigen receptors that target BCMA and CD19. The CAR may comprise an scFv targeting BCMA and an scFv targeting CD19, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasm signaling domain. Chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

The invention discloses an anti-TP53 mutation T cell receptor and application thereof, the T cell receptor comprises specific alpha chain and beta chain variable domains, and the complementary determining region (CDR) sequence is shown as SEQ ID NO: 9-14. The TCR has the core advantage that the TCR has excellent broad-spectrum recognition capability, can target six different amino acid substitutions (A, G, I, N, S and T) at the R249 site, and effectively deals with tumor heterogeneity and mutation difference between patients. Aiming at high-frequency HLA-B * 07: 02 alleles in people, the TCR lays a foundation for developing TCR-T cell therapy covering a wide range of people, and has great clinical application value and market potential in treatment of various solid tumors carrying TP53 R249 hotspot mutation, such as liver cancer.

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

The present disclosure relates to compounds that function as degraders or inhibitors of BTK. The present disclosure further relates to pharmaceutical compositions comprising them, and to their use in the treatment of diseases mediated by BTK, such as cancer.

The invention provides a monoclonal antibody targeting a human folate receptor alpha subtype. Specifically, a mouse is immunized through FR1 recombinant protein, and a monoclonal antibody with high affinity to FR1 is screened out. In addition, the invention also provides an amino acid sequence of the monoclonal antibody, nucleic acid containing the sequence, a carrier or a conjugate containing the nucleic acid, and application of the monoclonal antibody in FR1 overexpressed tumors / cancers.

The present disclosure relates to a method for ameliorating or treating malignant ascites using an anti-EpCAM × CD3 bispecific antibody and a composition thereof and use of the anti-EpCAM × CD3 bispecific antibody and a composition thereof in ameliorating or treating malignant ascites. The present disclosure features better dosing convenience, longer dosing intervals, longer dosing cycles, and improved efficacy and safety.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention discloses klebsiella aerogenes HW2024 and application of the klebsiella aerogenes HW2024 in preparation of drugs for treating allergic rhinitis. The preservation number of the klebsiella aerogenes HW2024 is CCTCC NO: M 20252524. The Klebsiella aerogenes disclosed by the invention is a symbiotic bacterium, and is relatively safe and easy to obtain, so that the treatment cost of AR patients can be greatly reduced, and a new treatment choice is provided for AR treatment; the pharmaceutical preparation for treating allergic rhinitis is simple and convenient in administration route, easy to operate and convenient for patients to use.

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

The invention belongs to the field of biological medicine, and discloses an oral flora marker related to tongue squamous cell carcinoma (TSCC) and application of the oral flora marker. The oral cavity flora marker is Stomatobacterium longum (SBL), and the oral cavity flora marker is SBL (Stomatobacterium longum); the invention further discloses a diagnostic product of the TSCC, application of the SBL in preparation of a medicine for treating the TSCC and the medicine for treating the TSCC. The diagnosis product prepared by taking the SBL as the marker can quickly and effectively carry out early diagnosis on the TSCC so as to achieve the purposes of early discovery, early treatment and improvement of the survival rate. The medicine provided by the invention can specifically inhibit the SBL from secreting the nano extracellular vesicles so as to inhibit the expression of BRCA1 and further inhibit the expression of EXO1 and TP53BP1, so that the proliferation and cell cycle progress of TSCC cells are inhibited, and the treatment on the TSCC is realized. The medicine has good specificity and can be used for effectively treating TSCC.

The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.

To provide a biomarker for clonal hematopoiesis.SOLUTION: The present inventors have found that PYY, LEP, SCN3A, FCGR2A, CYTH3, CD8A, TK1, GBP6, DSC2, GP5, IL17D, CD244, SLC4A1, BGN, APOA4, and MMP7 in a body fluid sample are biomarkers for clonal hematopoiesis.SELECTED DRAWING: None

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.